US47103J1051
US47103J1051
Janux Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 10.000.000 | 10.588.000 | 5.6% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 167.667.000 | 109.435.000 | 53.2% | |
| Operating Income | -157.667.000 | -98.847.000 | 59.5% |
| Pretax Income | -113.625.000 | -68.994.000 | 64.7% |
| Net Income Common Stockholders | -113.625.000 | -68.994.000 | 64.7% |
| -- | -- | -- | |
| -- | -- | -- |